Abstract
The development of human immunodeficiency virus type 1 resistance to delavirdine (DLV) was studied in subjects receiving DLV monotherapy. Phenotypic resistance developed in 28 of 30 subjects within 8 weeks. K103N and Y181C, which confer nonnucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance, were the predominant reverse transcriptase mutations. P236L, which confers DLV resistance but hypersensitivity to other NNRTIs, developed in <10% of isolates.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 794-797 |
| Number of pages | 4 |
| Journal | Antimicrobial agents and chemotherapy |
| Volume | 44 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2000 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Infectious Diseases
Fingerprint Dive into the research topics of 'Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)'. Together they form a unique fingerprint.
Cite this
Demeter, L. M., Shafer, R. W., Meehan, P. M., Holden-Wiltse, J., Fischl, M. A., Freimuth, W. W., Para, M. F., & Reichman, R. C. (2000). Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrobial agents and chemotherapy, 44(3), 794-797. https://doi.org/10.1128/AAC.44.3.794-797.2000